drugset / Trial / NCT03005678

Denosumab Versus Bisphosphonates (Alendronate) in GIOP

NCT03005678

Phase 4 Completed 140 enrolled Tuen Mun Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

A randomized controlled trial to compare for the efficacy and tolerability of denosumab and oral alendronate in the management of glucocorticoid induced osteoporosis

Timeline

Start
2017-04-01
Primary completion
2019-11-01
Completion
2020-02-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alendronic Acid Small molecule 70 mg Oral
Comparator Denosumab Monoclonal antibody 60 mg Subcutaneous

Indications